Abstract:That cancer cells show patterns of metabolism different from normal cells has been known for over 50 years. Yet, it is only in the past decade or so that an appreciation of the benefits of these changes has begun to emerge. Altered cancer cell metabolism was initially attributed to defective mitochondria. However, we now realize that most cancers do not have mitochondrial mutations and that normal cells can transiently adopt cancer-like metabolism during periods of rapid proliferation. Indeed, an encompassing, albeit somewhat simplified, conceptual framework to explain both normal and cancer cell metabolism rests on several simple premises. First, the metabolic pathways used by cancer cells and their normal counterparts are the same. Second, normal quiescent cells use their metabolic pathways and the energy they generate largely to maintain cellular health and organelle turnover and, in some cases, to provide secreted products necessary for the survival of the intact organism. By contrast, undifferentiated cancer cells minimize the latter functions and devote their energy to producing the anabolic substrates necessary to maintain high rates of unremitting cellular proliferation. Third, as a result of the uncontrolled proliferation of cancer cells, a larger fraction of the metabolic intermediates normally used by quiescent cells purely as a source of energy are instead channeled into competing proliferation-focused and energy-consuming anabolic pathways. Fourth, cancer cell clones with the most plastic and rapidly adaptable metabolism will eventually outcompete their less well-adapted brethren during tumor progression and evolution. This attribute becomes increasingly important as tumors grow and as their individual cells compete in a constantly changing and inimical environment marked by nutrient, oxygen, and growth factor deficits. Here, we review some of the metabolic pathways whose importance has gained center stage for tumor growth, particularly those under the control of the c-Myc (Myc) oncoprotein. We discuss how these pathways differ functionally between quiescent and proliferating normal cells, how they are kidnapped and corrupted during the course of transformation, and consider potential therapeutic strategies that take advantage of common features of neoplastic and metabolic disorders.

Examining Myc-Dependent Translation Changes in Cellular Homeostasis and Cancer

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer.

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

Functional screen for mediators of onco-mRNA translation specificity

Targeting Myc-driven stress addiction in colorectal cancer

MYC Promotes Cancer Progression by Modulating M6a Modifications to Suppress Target Gene Translation

MEDB-18. Elongation control of mRNA translation supports Group 3 medulloblastoma adaptation to nutrient deprivation

Regulation of c-Myc protein stability by proteasome activator REG γ

MYC promotes cancer progression by modulating m 6 A modifications to suppress target gene translation

Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat

Target gene-independent functions of MYC oncoproteins

MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications

Transcriptional regulation by MYC: an emerging new model

Transcriptional Regulation of Protein Synthesis by Mediator Kinase in MYC-driven Medulloblastoma

Cellular MYCro economics: Balancing MYC function with MYC expression

Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers

Metabolism and mRNA translation: a nexus of cancer plasticity

C-Myc Suppression of Mir-23A/b Enhances Mitochondrial Glutaminase Expression and Glutamine Metabolism.

A New Insight into MYC Action: Control of RNA Polymerase II Methylation and Transcription Termination